{"id":353545,"date":"2026-11-19T09:28:57","date_gmt":"2026-11-19T03:58:57","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=353545"},"modified":"2026-11-19T09:28:57","modified_gmt":"2026-11-19T03:58:57","slug":"anlon-healthcare-analyst-review","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/anlon-healthcare-analyst-review\/","title":{"rendered":"Anlon Healthcare Analyst Review 2027: Revenue Doubles and H1 Beats All of FY26"},"content":{"rendered":"<div style=\"background:#E8F1FF;border-left:5px solid #1565C0;padding:16px 20px;margin:0 0 20px 0;border-radius:6px;\">\n<p><strong>Anlon Healthcare Stock Snapshot (18 Nov 2026 close)<\/strong><\/p>\n<ul>\n<li><strong>Current Market Price (CMP):<\/strong> \u20b925.45<\/li>\n<li><strong>52-Week High \/ Low:<\/strong> \u20b937.24 \/ \u20b910.37<\/li>\n<li><strong>Market Capitalisation:<\/strong> \u20b91,352 crore<\/li>\n<li><strong>P\/E Ratio vs Industry P\/E:<\/strong> 32.6 vs 40.1<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Revenue:<\/strong> \u20b9105.61 crore<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Net Profit:<\/strong> \u20b917.18 crore<\/li>\n<\/ul>\n<\/div>\n<div style=\"background:#F0F9FF;border-left:5px solid #2E7D32;padding:16px 20px;margin:0 0 20px 0;\">\n<p><strong>Quick Answer:<\/strong> The <strong>Anlon Healthcare analyst review 2027<\/strong> finds no verified brokerage target as of November 2026. Q2 FY27 consolidated revenue rose about 102% to \u20b9105.61 crore and profit rose about 84% to \u20b917.18 crore, with EBITDA margin recovering to 23.9% from 17.8% in Q1. H1 revenue of \u20b9193.17 crore is already above FY26&#8217;s full-year total, and management reiterated FY27 revenue guidance of \u20b9380 crore to \u20b9400 crore. Operating cash flow was negative in FY25 and FY26, so the <strong>Anlon Healthcare share price target 2027<\/strong> depends on growth turning into cash.<\/p>\n<\/div>\n<p>The <strong>Anlon Healthcare analyst review 2027<\/strong> covers a chemical maker of pharmaceutical intermediates and active pharmaceutical ingredients that listed in 2025. Readers searching for an <strong>Anlon Healthcare share price target 2027<\/strong> will not find a named <strong>brokerage<\/strong> figure, so this review relies on reported results and management guidance.<\/p>\n<p><a href=\"https:\/\/univest.in\/stocks\/ahcl\/anlon-healthcare-limited-share-price-today\">Anlon Healthcare<\/a> closed at \u20b925.45 on 18 November 2026, about 32% below its 52-week high of \u20b937.24 and about 2.5 times its low of \u20b910.37. This Anlon Healthcare analyst review 2027 covers the September quarter, the acquisition-led growth and what will shape the <strong>Anlon Healthcare stock outlook 2027<\/strong>.<\/p>\n<p><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=anlon-healthcare-analyst-review\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/anlon-healthcare-analyst-review\/#What_Analysts_Say_in_the_Anlon_Healthcare_Analyst_Review_2027\" title=\"What Analysts Say in the Anlon Healthcare Analyst Review 2027\">What Analysts Say in the Anlon Healthcare Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/anlon-healthcare-analyst-review\/#Q2_FY27_Results_in_the_Anlon_Healthcare_Analyst_Review_2027\" title=\"Q2 FY27 Results in the Anlon Healthcare Analyst Review 2027\">Q2 FY27 Results in the Anlon Healthcare Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/anlon-healthcare-analyst-review\/#How_Anlon_Healthcare_Makes_Money\" title=\"How Anlon Healthcare Makes Money\">How Anlon Healthcare Makes Money<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/anlon-healthcare-analyst-review\/#Growth_Triggers_in_the_Anlon_Healthcare_Analyst_Review_2027\" title=\"Growth Triggers in the Anlon Healthcare Analyst Review 2027\">Growth Triggers in the Anlon Healthcare Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/anlon-healthcare-analyst-review\/#Key_Risks_in_the_Anlon_Healthcare_Analyst_Review_2027\" title=\"Key Risks in the Anlon Healthcare Analyst Review 2027\">Key Risks in the Anlon Healthcare Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/anlon-healthcare-analyst-review\/#Anlon_Healthcare_Analyst_Review_2027_Stock_at_a_Glance\" title=\"Anlon Healthcare Analyst Review 2027: Stock at a Glance\">Anlon Healthcare Analyst Review 2027: Stock at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/anlon-healthcare-analyst-review\/#Shareholding_Trend\" title=\"Shareholding Trend\">Shareholding Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/anlon-healthcare-analyst-review\/#What_to_Watch_After_the_Anlon_Healthcare_Analyst_Review_2027\" title=\"What to Watch After the Anlon Healthcare Analyst Review 2027\">What to Watch After the Anlon Healthcare Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/anlon-healthcare-analyst-review\/#Final_Word_on_the_Anlon_Healthcare_Analyst_Review_2027\" title=\"Final Word on the Anlon Healthcare Analyst Review 2027\">Final Word on the Anlon Healthcare Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/anlon-healthcare-analyst-review\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/anlon-healthcare-analyst-review\/#What_does_the_Anlon_Healthcare_analyst_review_2027_show\" title=\"What does the Anlon Healthcare analyst review 2027 show?\">What does the Anlon Healthcare analyst review 2027 show?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/anlon-healthcare-analyst-review\/#Is_there_an_Anlon_Healthcare_share_price_target_2027_from_brokerages\" title=\"Is there an Anlon Healthcare share price target 2027 from brokerages?\">Is there an Anlon Healthcare share price target 2027 from brokerages?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/anlon-healthcare-analyst-review\/#What_is_Anlon_Healthcares_FY27_guidance\" title=\"What is Anlon Healthcare&#8217;s FY27 guidance?\">What is Anlon Healthcare&#8217;s FY27 guidance?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/anlon-healthcare-analyst-review\/#How_does_Anlon_Healthcare_make_money\" title=\"How does Anlon Healthcare make money?\">How does Anlon Healthcare make money?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/anlon-healthcare-analyst-review\/#Is_Anlon_Healthcare_stock_expensive_based_on_the_Anlon_Healthcare_analyst_review_2027\" title=\"Is Anlon Healthcare stock expensive based on the Anlon Healthcare analyst review 2027?\">Is Anlon Healthcare stock expensive based on the Anlon Healthcare analyst review 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/anlon-healthcare-analyst-review\/#What_risks_does_the_Anlon_Healthcare_analyst_review_2027_highlight\" title=\"What risks does the Anlon Healthcare analyst review 2027 highlight?\">What risks does the Anlon Healthcare analyst review 2027 highlight?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/anlon-healthcare-analyst-review\/#What_should_investors_track_after_the_Anlon_Healthcare_analyst_review_2027\" title=\"What should investors track after the Anlon Healthcare analyst review 2027?\">What should investors track after the Anlon Healthcare analyst review 2027?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Analysts_Say_in_the_Anlon_Healthcare_Analyst_Review_2027\"><\/span><strong>What Analysts Say in the Anlon Healthcare Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Brokerage<\/th>\n<th>Rating<\/th>\n<th>Target Price<\/th>\n<th>Date<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>No verified coverage<\/td>\n<td>Not available<\/td>\n<td>Not available<\/td>\n<td>As of November 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>We could not verify a rating or target from a named <strong>brokerage<\/strong> as of November 2026. The company is recently listed and small, and institutions hold about 1% of its shares.<\/p>\n<p>Management&#8217;s revenue guidance is the clearest forward marker. FY27 revenue of \u20b9380 crore to \u20b9400 crore would be more than double FY26&#8217;s \u20b9172 crore. Any Anlon Healthcare share price target 2027 view needs to test that guidance against the second half, which this Anlon Healthcare analyst review 2027 does below.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY27_Results_in_the_Anlon_Healthcare_Analyst_Review_2027\"><\/span><strong>Q2 FY27 Results in the Anlon Healthcare Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Revenue<\/th>\n<th>EBITDA<\/th>\n<th>Net Profit<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Sep 2026 (Q2 FY27)<\/td>\n<td>\u20b9105.66 crore<\/td>\n<td>\u20b925.29 crore<\/td>\n<td>\u20b917.18 crore<\/td>\n<\/tr>\n<tr>\n<td>Jun 2026 (Q1 FY27)<\/td>\n<td>\u20b987.62 crore<\/td>\n<td>\u20b915.65 crore<\/td>\n<td>\u20b98.28 crore<\/td>\n<\/tr>\n<tr>\n<td>Mar 2026 (Q4 FY26)<\/td>\n<td>\u20b950.90 crore<\/td>\n<td>\u20b915.30 crore<\/td>\n<td>\u20b911.07 crore<\/td>\n<\/tr>\n<tr>\n<td>Dec 2025 (Q3 FY26)<\/td>\n<td>\u20b935.78 crore<\/td>\n<td>\u20b912.47 crore<\/td>\n<td>\u20b95.15 crore<\/td>\n<\/tr>\n<tr>\n<td>Sep 2025 (Q2 FY26)<\/td>\n<td>\u20b952.23 crore<\/td>\n<td>\u20b913.73 crore<\/td>\n<td>\u20b99.32 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Consolidated revenue rose about 102% to \u20b9105.61 crore from \u20b952.2 crore. <strong>EBITDA<\/strong> margin recovered to 23.9% from 17.8% in Q1 after price revisions with customers, though it stayed below 26.3% a year earlier. <strong>Net profit<\/strong> rose about 84% to \u20b917.18 crore.<\/p>\n<p>Standalone revenue grew a slower 15.9% to \u20b960.5 crore, so much of the jump came from acquired businesses consolidated into the group. For the Anlon Healthcare analyst review 2027, organic and acquired growth need to be read separately.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Anlon_Healthcare_Makes_Money\"><\/span><strong>How Anlon Healthcare Makes Money<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Anlon sells chemical building blocks and finished drug ingredients to pharmaceutical companies.<\/p>\n<ul>\n<li><strong>Pharmaceutical intermediates:<\/strong> high-purity compounds used as starting materials for APIs.<\/li>\n<li><strong>Active pharmaceutical ingredients:<\/strong> finished ingredients sold to formulation makers.<\/li>\n<li><strong>Acquired capacity:<\/strong> Apiqo Organics, acquired in FY26, adds capacity and backward integration.<\/li>\n<li><strong>New molecules:<\/strong> several APIs are in validation, with commercial supplies targeted from Q3 FY27 onward.<\/li>\n<\/ul>\n<p>Revenue rose from about \u20b9120.5 crore in FY25 to \u20b9172.2 crore in FY26, and profit from \u20b920.5 crore to \u20b929.1 crore. Operating cash flow was negative in both years, at about minus \u20b922 crore and minus \u20b959 crore, as working capital grew. That cash gap is the main caution in the Anlon Healthcare analyst review 2027.<\/p>\n<p>Intermediates and APIs are business-to-business products, so a few large customer orders can shift a quarter. Pricing also moves with raw material costs, which explains why margin fell sharply in Q1 before customer price revisions restored it in Q2. Backward integration through Apiqo should, over time, give Anlon more control over input costs, but the benefit only began to flow from <strong>Q2 FY27<\/strong>, according to management.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Growth_Triggers_in_the_Anlon_Healthcare_Analyst_Review_2027\"><\/span><strong>Growth Triggers in the Anlon Healthcare Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Guidance:<\/strong> FY27 revenue of \u20b9380 crore to \u20b9400 crore, more than double FY26.<\/li>\n<li><strong>Margin floor:<\/strong> management guides to an <strong>EBITDA<\/strong> margin of at least 24% to 25%, with an aim of 25% to 30%.<\/li>\n<li><strong>New APIs:<\/strong> molecules moving from validation to commercial supply in late FY27.<\/li>\n<li><strong>Anlon Medicos:<\/strong> revenue from this unit expected from Q4 FY27.<\/li>\n<li><strong>Moderate debt:<\/strong> <strong>debt to equity<\/strong> of about 0.28 supports the Anlon Healthcare share price target 2027 case.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_in_the_Anlon_Healthcare_Analyst_Review_2027\"><\/span><strong>Key Risks in the Anlon Healthcare Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Negative cash flow:<\/strong> operating cash flow was negative in FY25 and FY26.<\/li>\n<li><strong>High inventory:<\/strong> inventory rose with the Apiqo consolidation and raw material inflation.<\/li>\n<li><strong>Regulatory delays:<\/strong> Anlon Medicos revenue was pushed out because of approvals.<\/li>\n<li><strong>Margin volatility:<\/strong> <strong>EBITDA<\/strong> margin swung from 26.3% to 17.8% and back to 23.9% within a year.<\/li>\n<li><strong>Institutional exit:<\/strong> DII holding fell to 0.06% from 2.83%, a caution in the Anlon Healthcare analyst review 2027.<\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/univest.in\/screeners\">Compare Anlon Healthcare With Other Pharma Stocks on the Univest Screener<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Anlon_Healthcare_Analyst_Review_2027_Stock_at_a_Glance\"><\/span><strong>Anlon Healthcare Analyst Review 2027: Stock at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Share Price (18 Nov 2026 close)<\/td>\n<td>\u20b925.45<\/td>\n<\/tr>\n<tr>\n<td>52-Week High \/ Low<\/td>\n<td>\u20b937.24 \/ \u20b910.37<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>\u20b91,352 crore<\/td>\n<\/tr>\n<tr>\n<td>P\/E (TTM) vs Industry<\/td>\n<td>32.6 vs 40.1<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>5.25<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share<\/td>\n<td>\u20b94.84<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>13.86%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.28<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>\u20b90.78<\/td>\n<\/tr>\n<tr>\n<td>FY26 Revenue \/ Net Profit<\/td>\n<td>\u20b9172 crore \/ \u20b929 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>A <strong>P\/E<\/strong> of about 32.6 is below the pharma industry figure of about 40, while price to <strong>book value<\/strong> is about 5.3. In the Anlon Healthcare analyst review 2027, the multiple looks reasonable only if guidance is met.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Shareholding_Trend\"><\/span><strong>Shareholding Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Holder<\/th>\n<th>Sep 2025<\/th>\n<th>Sep 2026<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Promoters<\/td>\n<td>52.68%<\/td>\n<td>52.68%<\/td>\n<td>No change<\/td>\n<\/tr>\n<tr>\n<td>Foreign Investors (FII)<\/td>\n<td>0.00%<\/td>\n<td>1.00%<\/td>\n<td>Up 1.00 pt<\/td>\n<\/tr>\n<tr>\n<td>Domestic Institutions (DII)<\/td>\n<td>2.83%<\/td>\n<td>0.06%<\/td>\n<td>Down 2.77 pts<\/td>\n<\/tr>\n<tr>\n<td>Public<\/td>\n<td>44.49%<\/td>\n<td>46.26%<\/td>\n<td>Up 1.77 pts<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The <strong>promoter<\/strong> group holds 52.68%, led by Punitkumar Rasadia at 34.98% and Meet Vachhani at 17.7%. Domestic funds that held shares after listing have almost fully exited, while a small foreign stake appeared. Thin institutional ownership is part of the Anlon Healthcare analyst review 2027.<\/p>\n<p><strong><a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_to_Watch_After_the_Anlon_Healthcare_Analyst_Review_2027\"><\/span><strong>What to Watch After the Anlon Healthcare Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Guidance delivery:<\/strong> H2 revenue needs about \u20b9187 crore to \u20b9207 crore to meet FY27 guidance.<\/li>\n<li><strong>Cash flow:<\/strong> a turn to positive operating cash flow.<\/li>\n<li><strong>Inventory:<\/strong> the planned 20% to 25% liquidation of excess stock.<\/li>\n<li><strong>New products:<\/strong> commercial supply from APIs in validation.<\/li>\n<li><strong>Research coverage:<\/strong> a first named note would give an Anlon Healthcare share price target 2027 reference.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Final_Word_on_the_Anlon_Healthcare_Analyst_Review_2027\"><\/span><strong>Final Word on the Anlon Healthcare Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Anlon Healthcare analyst review 2027<\/strong> shows a young listed API company that doubled revenue in Q2 and already beat its FY26 revenue in six months. Much of the growth came from acquisitions, cash flow has been negative and institutions have exited.<\/p>\n<p>The <strong>Anlon Healthcare stock outlook 2027<\/strong> depends on meeting FY27 guidance, cash conversion and new product launches. Univest does not give a buy or sell call.<\/p>\n<div style=\"background:#FFF5F5;border-left:5px solid #C62828;padding:14px 18px;margin:24px 0;\">\n<p style=\"color:#C62828;\"><strong>Disclaimer:<\/strong> This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div class=\"faq-schema\">\n<h3><span class=\"ez-toc-section\" id=\"What_does_the_Anlon_Healthcare_analyst_review_2027_show\"><\/span><strong>What does the Anlon Healthcare analyst review 2027 show?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>It shows rapid growth led partly by acquisitions. Q2 FY27 revenue rose about 102% to \u20b9105.61 crore. Profit rose about 84% to \u20b917.18 crore. H1 revenue of \u20b9193.17 crore is already above FY26&#8217;s total.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_there_an_Anlon_Healthcare_share_price_target_2027_from_brokerages\"><\/span><strong>Is there an Anlon Healthcare share price target 2027 from brokerages?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>We could not verify a named brokerage target as of November 2026. The stock closed at \u20b925.45 on 18 November 2026. It trades about 32% below its 52-week high of \u20b937.24.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Anlon_Healthcares_FY27_guidance\"><\/span><strong>What is Anlon Healthcare&#8217;s FY27 guidance?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Management guides FY27 revenue of \u20b9380 crore to \u20b9400 crore. That needs about \u20b9187 crore to \u20b9207 crore in H2. EBITDA margin is guided at a floor of about 24% to 25%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_Anlon_Healthcare_make_money\"><\/span><strong>How does Anlon Healthcare make money?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>It sells pharmaceutical intermediates and active pharmaceutical ingredients to drug makers. It acquired Apiqo Organics in FY26 for capacity. FY26 revenue was about \u20b9172 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Anlon_Healthcare_stock_expensive_based_on_the_Anlon_Healthcare_analyst_review_2027\"><\/span><strong>Is Anlon Healthcare stock expensive based on the Anlon Healthcare analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The P\/E of about 32.6 is below the industry figure of about 40. Price to book is about 5.3. Return on equity is about 13.9%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_does_the_Anlon_Healthcare_analyst_review_2027_highlight\"><\/span><strong>What risks does the Anlon Healthcare analyst review 2027 highlight?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The main risks are negative cash flow, high inventory and regulatory delays. Operating cash flow was about minus \u20b959 crore in FY26. Domestic institutions cut their stake to 0.06% from 2.83%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_investors_track_after_the_Anlon_Healthcare_analyst_review_2027\"><\/span><strong>What should investors track after the Anlon Healthcare analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track whether H2 revenue reaches \u20b9187 crore to \u20b9207 crore. Watch for positive operating cash flow and lower inventory. Commercial supply from new APIs is another key test.<\/p>\n<\/div>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does the Anlon Healthcare analyst review 2027 show?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It shows rapid growth led partly by acquisitions. Q2 FY27 revenue rose about 102% to \u20b9105.61 crore. Profit rose about 84% to \u20b917.18 crore. H1 revenue of \u20b9193.17 crore is already above FY26's total.\"}},{\"@type\":\"Question\",\"name\":\"Is there an Anlon Healthcare share price target 2027 from brokerages?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"We could not verify a named brokerage target as of November 2026. The stock closed at \u20b925.45 on 18 November 2026. It trades about 32% below its 52-week high of \u20b937.24.\"}},{\"@type\":\"Question\",\"name\":\"What is Anlon Healthcare's FY27 guidance?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Management guides FY27 revenue of \u20b9380 crore to \u20b9400 crore. That needs about \u20b9187 crore to \u20b9207 crore in H2. EBITDA margin is guided at a floor of about 24% to 25%.\"}},{\"@type\":\"Question\",\"name\":\"How does Anlon Healthcare make money?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It sells pharmaceutical intermediates and active pharmaceutical ingredients to drug makers. It acquired Apiqo Organics in FY26 for capacity. FY26 revenue was about \u20b9172 crore.\"}},{\"@type\":\"Question\",\"name\":\"Is Anlon Healthcare stock expensive based on the Anlon Healthcare analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The P\/E of about 32.6 is below the industry figure of about 40. Price to book is about 5.3. Return on equity is about 13.9%.\"}},{\"@type\":\"Question\",\"name\":\"What risks does the Anlon Healthcare analyst review 2027 highlight?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are negative cash flow, high inventory and regulatory delays. Operating cash flow was about minus \u20b959 crore in FY26. Domestic institutions cut their stake to 0.06% from 2.83%.\"}},{\"@type\":\"Question\",\"name\":\"What should investors track after the Anlon Healthcare analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Track whether H2 revenue reaches \u20b9187 crore to \u20b9207 crore. Watch for positive operating cash flow and lower inventory. Commercial supply from new APIs is another key test.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Anlon Healthcare roughly doubled Q2 FY27 revenue to \u20b9105.61 crore and grew profit about 84% to \u20b917.18 crore, with H1 revenue already above FY26&#8217;s total. With no verified brokerage target, we review results, guidance, cash flow, valuation and risks.<\/p>\n","protected":false},"author":35,"featured_media":353542,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[24444,4341,26018,26019],"class_list":["post-353545","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-24444","tag-analyst-review","tag-anlon-healthcare","tag-pharmaceuticals-intermediates-and-apis"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["353542"],"rank_math_title":["Anlon Healthcare Share Price Target 2027: Review"],"rank_math_description":["Anlon Healthcare analyst review 2027: Q2 FY27 revenue doubles to \u20b9105.61 crore, profit up 84%, \u20b9380 to \u20b9400 crore FY27 guidance, cash flow and key risks."],"rank_math_focus_keyword":["Anlon Healthcare analyst review 2027"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/anlon-healthcare-analyst-review-2027-revenue-doubles-and-h1-beats-all-of-fy26.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/353545","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=353545"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/353545\/revisions"}],"predecessor-version":[{"id":353547,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/353545\/revisions\/353547"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/353542"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=353545"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=353545"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=353545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}